Exploring the value of apoB48 as a marker for atherosclerosis in clinical practice

Eur J Clin Invest 2012; 42 (7): 702–708 Background  Postprandial accumulation of atherogenic remnants has been described in patients with type 2 diabetes mellitus (T2DM), familial combined hyperlipidaemia (FCH), familial hypercholesterolaemia (FH) and coronary artery disease (CAD). Scarce data are a...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical investigation 2012-07, Vol.42 (7), p.702-708
Main Authors: Alipour, Arash, Valdivielso, Pedro, Elte, Jan Willem F., Janssen, Hans W., Rioja, Jose, van der Meulen, Noëlle, van Mechelen, Rob, Njo, Tjin L., González-Santos, Pedro, Rietveld, Arie P., Cabezas, Manuel Castro
Format: Article
Language:English
Subjects:
Aged
Analysis of Variance
Apolipoprotein B-48 - blood
Apolipoprotein B48
Atherosclerosis (general aspects, experimental research)
Atherosclerosis - blood
Biological and medical sciences
Biomarkers - blood
Blood and lymphatic vessels
Cardiology. Vascular system
Carotid Intima-Media Thickness
Case-Control Studies
coronary artery disease
Coronary heart disease
Diabetes Mellitus, Type 2 - blood
familial lipid disorders
Fasting
Female
General aspects
Heart
Humans
Hyperlipidemia, Familial Combined - blood
intima-media thickness
Male
Medical sciences
Middle Aged
type 2 diabetes mellitus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Eur J Clin Invest 2012; 42 (7): 702–708 Background  Postprandial accumulation of atherogenic remnants has been described in patients with type 2 diabetes mellitus (T2DM), familial combined hyperlipidaemia (FCH), familial hypercholesterolaemia (FH) and coronary artery disease (CAD). Scarce data are available on fasting plasma apolipoprotein (apo) B48 levels in relation to these conditions and atherosclerosis. Design  Treated patients with FCH (18), FH (20), T2DM (26), CAD (65), T2DM with CAD (T2DM/CAD) (28) and 33 healthy controls were included. Intima‐media thickness (IMT) measurements were carried out to investigate subclinical atherosclerosis. Results  LDL‐C and total apoB were lowest in patients with T2DM/CAD owing to the more frequent use of lipid‐lowering medication. Fasting plasma apoB48 was elevated in patients with FCH (11·38 ± 1·50 mg/L) and T2DM/CAD (9·65 ± 1·14 mg/L) compared with the other groups (anova, P 
ISSN:0014-2972
1365-2362
DOI:10.1111/j.1365-2362.2011.02635.x